Aptose Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-25.43	-51.21	-41.82	-65.35	-55.24	Upgrade
Depreciation & Amortization	0.4	0.47	0.53	0.62	0.61	Upgrade
Loss (Gain) From Sale of Assets	0.08	-	0.02	-	-	Upgrade
Stock-Based Compensation	1.06	3.65	5.21	12.95	21.44	Upgrade
Other Operating Activities	-0.6	0.09	-0.02	7.52	0.09	Upgrade
Change in Accounts Payable	-4.79	-0.28	7.61	-0.47	0.21	Upgrade
Change in Other Net Operating Assets	-6.7	2.69	-3.84	1.43	-1.01	Upgrade
Operating Cash Flow	-35.98	-44.59	-32.32	-43.3	-33.89	Upgrade
Capital Expenditures	-0.01	-0.03	-0.02	-0.21	-0.08	Upgrade
Sale of Property, Plant & Equipment	0.02	-	-	-	-	Upgrade
Investment in Securities	-	9.99	30.09	-35	12.71	Upgrade
Investing Cash Flow	0.02	9.96	30.07	-35.21	12.63	Upgrade
Long-Term Debt Issued	10	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	10	-	-	-	-	Upgrade
Issuance of Common Stock	23.44	6.91	0.12	0.23	58.98	Upgrade
Other Financing Activities	-0.02	-	-	-	-0.17	Upgrade
Financing Cash Flow	33.41	6.91	0.12	0.23	58.81	Upgrade
Foreign Exchange Rate Adjustments	-	0	-0	0.01	0.01	Upgrade
Net Cash Flow	-2.55	-27.72	-2.14	-78.28	37.55	Upgrade
Free Cash Flow	-35.98	-44.62	-32.35	-43.52	-33.97	Upgrade
Free Cash Flow Per Share	-51.48	-198.17	-157.76	-219.81	-186.79	Upgrade
Levered Free Cash Flow	-26.66	-25.82	-16.6	-26.03	-13.14	Upgrade
Unlevered Free Cash Flow	-26.53	-25.82	-16.6	-26.03	-13.14	Upgrade
Change in Net Working Capital	11.58	-2.81	-4.32	-1.52	0.26	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.